- Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits.
- Aytu has significant upside potential and numerous exciting catalysts to be announced that could drive significant share price value in the very near future.
- Recent news of a huge value-adding merger with Neos Therapeutics and completion of the initial phase of the Healight trial to treat Covid-19 are the first of many catalysts.
For further details see:
Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts